SG176921A1 - Diazahomoadamantane derivatives and methods of use thereof - Google Patents

Diazahomoadamantane derivatives and methods of use thereof Download PDF

Info

Publication number
SG176921A1
SG176921A1 SG2011094141A SG2011094141A SG176921A1 SG 176921 A1 SG176921 A1 SG 176921A1 SG 2011094141 A SG2011094141 A SG 2011094141A SG 2011094141 A SG2011094141 A SG 2011094141A SG 176921 A1 SG176921 A1 SG 176921A1
Authority
SG
Singapore
Prior art keywords
diazatricyclo
jundecane
pyridin
alkyl
lundecane
Prior art date
Application number
SG2011094141A
Other languages
English (en)
Inventor
Michael R Schrimpf
Kevin B Sippy
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43354879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG176921(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SG176921A1 publication Critical patent/SG176921A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
SG2011094141A 2009-06-19 2010-06-18 Diazahomoadamantane derivatives and methods of use thereof SG176921A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21847909P 2009-06-19 2009-06-19
PCT/CN2010/000889 WO2010145208A1 (en) 2009-06-19 2010-06-18 Diazahomoadamantane derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
SG176921A1 true SG176921A1 (en) 2012-01-30

Family

ID=43354879

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011094141A SG176921A1 (en) 2009-06-19 2010-06-18 Diazahomoadamantane derivatives and methods of use thereof

Country Status (15)

Country Link
US (1) US8846661B2 (https=)
EP (1) EP2443122B1 (https=)
JP (1) JP2012530084A (https=)
KR (1) KR20120044978A (https=)
CN (1) CN102459268A (https=)
AU (1) AU2010262643B2 (https=)
BR (1) BRPI1015043A2 (https=)
CA (1) CA2765466A1 (https=)
IL (2) IL216883A (https=)
MX (1) MX2011014019A (https=)
NZ (1) NZ597511A (https=)
PE (1) PE20121066A1 (https=)
RU (2) RU2549551C2 (https=)
SG (1) SG176921A1 (https=)
WO (1) WO2010145208A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024615A1 (en) * 2010-08-20 2012-02-23 Research Triangle Institute Nicotinic receptor compounds
CN103087001A (zh) * 2011-11-03 2013-05-08 南京大学 香草酸的1,3,4-噁二唑衍生物及其制法和用途
US10301294B2 (en) 2013-03-13 2019-05-28 The Broad Institute Inc. Compounds for the treatment of tuberculosis
RU2552649C1 (ru) * 2013-12-13 2015-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) Душистые 5-бензил-1,3-диазаадамантан-6-оны
WO2015103005A1 (en) * 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MX2017016231A (es) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
WO2019155468A1 (en) * 2018-02-08 2019-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
HRP20240935T1 (hr) 2018-06-27 2024-11-22 Ptc Therapeutics, Inc. Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
JP7649257B2 (ja) 2019-05-13 2025-03-19 ピーティーシー セラピューティクス, インコーポレイテッド ハンチントン病を処置するための化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557865A (en) * 1984-05-07 1985-12-10 Pennwalt Corporation Substituted 4-azatricyclo[4.3.1.13,8 ]undecane compounds
EE03566B1 (et) * 1995-11-02 2001-12-17 Neurosearch A/S Kondenseerunud tropaanderivaadid, nende valmistamine ja kasutamine
TR200100462T2 (tr) * 1998-08-18 2001-09-21 Ucb, S.A. Muskarinik agonistleri ve antagonistleri
CN1332726A (zh) * 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
BR0210391A (pt) * 2001-06-12 2004-06-15 Elan Pharm Inc Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
ATE363484T1 (de) * 2003-09-26 2007-06-15 Astrazeneca Ab Nichtamidnonane
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
MX2009010175A (es) * 2007-03-23 2009-10-12 Abbott Lab Derivados de acetamida y carboxamida de aza-adamantano y metodos de uso de los mismos.
ATE509931T1 (de) * 2007-03-23 2011-06-15 Abbott Lab Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
CA2679885A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Aminomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)
WO2011030349A1 (en) * 2009-09-14 2011-03-17 Suven Life Sciences Limited L -dihydro-2-oxoquinoline compounds a 5-ht4 receptor ligands

Also Published As

Publication number Publication date
AU2010262643B2 (en) 2015-02-19
EP2443122A1 (en) 2012-04-25
IL236830A0 (en) 2015-03-31
IL216883A (en) 2015-02-26
RU2015110025A (ru) 2015-08-20
RU2549551C2 (ru) 2015-04-27
CA2765466A1 (en) 2010-12-23
AU2010262643A1 (en) 2012-02-02
BRPI1015043A2 (pt) 2019-07-09
JP2012530084A (ja) 2012-11-29
RU2012101784A (ru) 2013-07-27
CN102459268A (zh) 2012-05-16
PE20121066A1 (es) 2012-09-13
US8846661B2 (en) 2014-09-30
MX2011014019A (es) 2012-02-22
NZ597511A (en) 2014-01-31
EP2443122A4 (en) 2012-12-19
WO2010145208A1 (en) 2010-12-23
US20100324027A1 (en) 2010-12-23
KR20120044978A (ko) 2012-05-08
EP2443122B1 (en) 2014-03-05
IL216883A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
EP2443122B1 (en) Diazahomoadamantane derivatives and methods of use thereof
US8163916B2 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
US20120196890A1 (en) 4-substituted azaadamantane derivatives and methods of use thereof
EP2505588B1 (en) process for preparing AMINOMETHYL AZAADAMANTANE DERIVATIVES as SELECTIVE MODULATORS OF THE ALPHA7- NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR (NNRS)
US20120190706A1 (en) Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
AU2015202090A1 (en) Diazahomoadamantane derivatives and methods of use thereof
HK1131609B (en) Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
HK1133642B (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
HK1135972B (en) 4-substituted azaadamantane derivatives and methods of use thereof